Smarter leaders trust GlobalData

Data Insights Cell & gene therapy in pharma: pancreatic cell transplantation

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Johnson & Johnson

Astellas Pharma Inc

United Therapeutics Corp

Geron Corp

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Pancreatic cell transplantation is a key innovation area in cell & gene therapy

Pancreatic cell transplantation is a medical procedure in which cells from the pancreas of a donor are transplanted into the pancreas of a recipient. The procedure’s goal is to replace damaged or nonfunctioning pancreatic cells in individuals with diabetes so that they can produce insulin and regulate their blood sugar levels more effectively.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 190+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of pancreatic cell transplantation.

Key players in pancreatic cell transplantation – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to pancreatic cell transplantation

Vertex Pharmaceuticals, is one of the leading patent filers in pancreatic cell transplantation. The company discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for treating cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. Vertex got approval for its genome editing technology based drug Casgevy. Some of the cell-based pipeline drugs include CTX-211, OBX-115 and VC-01. Johnson & Johnson and Astellas Pharma are some of the other key patent filers in pancreatic cell transplantation.

In terms of application diversity, Allele Biotechnology and Pharmaceuticals leads the pack, while Geron and United Therapeutics stood in second and third positions, respectively.

By means of geographic reach, United Therapeutics held the top position, followed by Accelerated Biosciences and Defymed.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.